RDUS Research and Charts

RDUS - Radius Health Inc (Healthcare: Drug Manufacturers - Specialty & Generic)

Projected Earnings Date: 2025-04-08 (Delayed quote data 2025-05-09)

Last 29.34	Change ⇓ -0.04 (-0.14%)	Volume 283,487
	Open 29.40	High 29.40	Low 29.33

8EMA (Daily) 29.35	40EMA (Daily) 27.05	50EMA (Daily) 26.04	STO (Daily) 84.848	MACD Hist (Daily) -0.512
8EMA (Weekly) 27.541	40EMA (Weekly) 20.65	50EMA (Weekly) 20.12	STO (Weekly) 99.507	MACD Hist (Weekly) 2.148


Company Profile
Radius Health Inc is an integrated biopharmaceutical company. It develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company's product, TYMLOS, is for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. The product pipeline of the company includes Abaloparatide-patch for the treatment of postmenopausal women with osteoporosis, Elacestrant, and RAD140. It primarily operates the business in the United States of America and generates key revenue from the sales of TYMLOS.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.